Ruxolitinib Cream 1.5%

DRUG2 trials

Sponsors

Incyte Corporation, Hospital Authority, Hong Kong

Conditions

Prurigo NodularisVitiligo

Phase 1

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

CompletedNCT06213831

Incyte CorporationPrurigo Nodularis

Start: 2024-02-27End: 2025-07-17Updated: 2025-08-13

Phase 2

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

RecruitingNCT06719024

Hospital Authority, Hong KongVitiligo

Start: 2024-11-29End: 2026-01-30Target: 20Updated: 2024-12-05